Systematic analysis of homologous recombination deficiency testing in ovarian cancer: development of recommendations for optimal assay performance
Homologous recombination deficiency (HRD) assays are an important element of personalized oncology in ovarian carcinomas, but the optimal tissue requirements for these complex molecular assays remain unclear. As a result, a considerable percentage of assays are not successful, leading to suboptimal...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
8 February 2024
|
| In: |
Modern pathology
Year: 2024, Volume: 37, Issue: 4 |
| ISSN: | 1530-0285 |
| DOI: | 10.1016/j.modpat.2024.100445 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.modpat.2024.100445 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0893395224000255 
|
| Author Notes: | Marcel Romey, Fiona Rodepeter, Akira Hattesohl, Kristin Kaiser, Julia Teply-Szymanski, Florian Heitz, Annette Staebler, Violeta Serra, Albert Grass, Frederik Marmé, Kirsten M. Timms, Philipp Harter, Alba Llop-Guevara, Stefan Kommoss, Jelena Boekhoff, Carsten Denkert |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1909392790 | ||
| 003 | DE-627 | ||
| 005 | 20241205222211.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 241122s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.modpat.2024.100445 |2 doi | |
| 035 | |a (DE-627)1909392790 | ||
| 035 | |a (DE-599)KXP1909392790 | ||
| 035 | |a (OCoLC)1475648013 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Romey, Marcel |e VerfasserIn |0 (DE-588)1349033561 |0 (DE-627)1909393150 |4 aut | |
| 245 | 1 | 0 | |a Systematic analysis of homologous recombination deficiency testing in ovarian cancer |b development of recommendations for optimal assay performance |c Marcel Romey, Fiona Rodepeter, Akira Hattesohl, Kristin Kaiser, Julia Teply-Szymanski, Florian Heitz, Annette Staebler, Violeta Serra, Albert Grass, Frederik Marmé, Kirsten M. Timms, Philipp Harter, Alba Llop-Guevara, Stefan Kommoss, Jelena Boekhoff, Carsten Denkert |
| 264 | 1 | |c 8 February 2024 | |
| 300 | |a 100445-1-100445-10$t10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 22.11.2024 | ||
| 520 | |a Homologous recombination deficiency (HRD) assays are an important element of personalized oncology in ovarian carcinomas, but the optimal tissue requirements for these complex molecular assays remain unclear. As a result, a considerable percentage of assays are not successful, leading to suboptimal diagnoses for these patients. In this study, we have systematically analyzed tumor and tissue parameters for HRD analysis in a large cohort of real-world cancer samples. The aim of this study is to give recommendations for pathologists and gynecologic oncologists for selection of tissue samples to maximize the success rate of HRD analyses. Tumor samples from 2702 patients were sent to the Institute of Pathology of the Philipps-University Marburg between October 2020 and September 2022, of which 2654 were analyzed using the Myriad MyChoice HRD+ CDx assay. A total of 2396 of 2654 samples (90.3%) were successfully tested, of which 984 of 2396 (41.1%) were HRD positive and 1412 (58.9%) were HRD negative. Three hundred sixty-three of 2396 samples (15.2%) were BRCA1/2-mutated; 27 samples had a BRCA1/2 mutation and a genomic instability score (GIS) < 42. Twenty-two samples (0.9%) failed GIS measurement but displayed a BRCA1/2 mutation. BRCA1/2-mutated samples showed significantly (P < .0001) higher GIS values than those with a wild-type BRCA1/2 status. Tumor cell content, tumor area, and histology significantly (P < .0001) affected the probability of successfully analyzing a sample. Based on a systematic analysis of tumor cell content and tumor area, we recommend selecting patient high-grade serous ovarian cancer samples that display a tumor cell content ≥30% and a tumor area ≥0.5 cm2 (based on their hematoxylin and eosin) for HRD testing to allow for optimal chances of a successful analysis and conclusive results. Considering histologic and sample conditions, success rates of up to 98% can be achieved. Our comprehensive evaluation contributes to further standardization of recommendations on HRD testing in ovarian cancer, which will have a large impact on personalized therapeutic strategies in this highly aggressive tumor type. | ||
| 650 | 4 | |a BRCA | |
| 650 | 4 | |a histology | |
| 650 | 4 | |a homologous recombination deficiency | |
| 650 | 4 | |a ovarian cancer | |
| 700 | 1 | |a Rodepeter, Fiona Rosali |d 1984- |e VerfasserIn |0 (DE-588)1051121485 |0 (DE-627)785824405 |0 (DE-576)405866933 |4 aut | |
| 700 | 1 | |a Hattesohl, Akira |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kaiser, Kristin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Teply-Szymanski, Julia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Heitz, Florian |d 1976- |e VerfasserIn |0 (DE-588)13714220X |0 (DE-627)590336347 |0 (DE-576)30237051X |4 aut | |
| 700 | 1 | |a Staebler, Annette |e VerfasserIn |4 aut | |
| 700 | 1 | |a Serra, Violeta |e VerfasserIn |0 (DE-588)1275920381 |0 (DE-627)1905605595 |4 aut | |
| 700 | 1 | |a Grass, Albert |d 1989- |e VerfasserIn |0 (DE-588)1221083961 |0 (DE-627)1738240436 |4 aut | |
| 700 | 1 | |a Marmé, Frederik |d 1974- |e VerfasserIn |0 (DE-588)132561972 |0 (DE-627)52394893X |0 (DE-576)299226549 |4 aut | |
| 700 | 1 | |a Timms, Kirsten M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Harter, Philipp |d 1971- |e VerfasserIn |0 (DE-588)123210208 |0 (DE-627)082414432 |0 (DE-576)293606552 |4 aut | |
| 700 | 1 | |a Llop-Guevara, Alba |e VerfasserIn |0 (DE-588)1250847397 |0 (DE-627)1788315154 |4 aut | |
| 700 | 1 | |a Kommoss, Stefan |d 1978- |e VerfasserIn |0 (DE-588)13261555X |0 (DE-627)690728115 |0 (DE-576)299258467 |4 aut | |
| 700 | 1 | |a Boekhoff, Jelena |d 1981- |e VerfasserIn |0 (DE-588)137594569 |0 (DE-627)695891766 |0 (DE-576)304488488 |4 aut | |
| 700 | 1 | |a Denkert, Carsten |d 1969- |e VerfasserIn |0 (DE-588)118129929 |0 (DE-627)079261124 |0 (DE-576)291730604 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Modern pathology |d London : Nature Publishing Group, 1988 |g 37(2024), 4, Artikel-ID 100445 |h Online-Ressource |w (DE-627)326643419 |w (DE-600)2041318-X |w (DE-576)283165553 |x 1530-0285 |7 nnas |a Systematic analysis of homologous recombination deficiency testing in ovarian cancer development of recommendations for optimal assay performance |
| 773 | 1 | 8 | |g volume:37 |g year:2024 |g number:4 |g elocationid:100445 |g extent:100445-1-100445-10$t10 |a Systematic analysis of homologous recombination deficiency testing in ovarian cancer development of recommendations for optimal assay performance |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.modpat.2024.100445 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S0893395224000255 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20241122 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 132561972 |a Marmé, Frederik |m 132561972:Marmé, Frederik |d 60000 |d 61300 |d 50000 |e 60000PM132561972 |e 61300PM132561972 |e 50000PM132561972 |k 0/60000/ |k 1/60000/61300/ |k 0/50000/ |p 10 | ||
| 999 | |a KXP-PPN1909392790 |e 4621378759 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"person":[{"family":"Romey","display":"Romey, Marcel","role":"aut","given":"Marcel"},{"family":"Rodepeter","display":"Rodepeter, Fiona Rosali","role":"aut","given":"Fiona Rosali"},{"family":"Hattesohl","display":"Hattesohl, Akira","role":"aut","given":"Akira"},{"family":"Kaiser","display":"Kaiser, Kristin","role":"aut","given":"Kristin"},{"display":"Teply-Szymanski, Julia","family":"Teply-Szymanski","role":"aut","given":"Julia"},{"family":"Heitz","display":"Heitz, Florian","given":"Florian","role":"aut"},{"display":"Staebler, Annette","family":"Staebler","given":"Annette","role":"aut"},{"given":"Violeta","role":"aut","family":"Serra","display":"Serra, Violeta"},{"display":"Grass, Albert","family":"Grass","role":"aut","given":"Albert"},{"display":"Marmé, Frederik","family":"Marmé","role":"aut","given":"Frederik"},{"role":"aut","given":"Kirsten M.","display":"Timms, Kirsten M.","family":"Timms"},{"role":"aut","given":"Philipp","display":"Harter, Philipp","family":"Harter"},{"family":"Llop-Guevara","display":"Llop-Guevara, Alba","role":"aut","given":"Alba"},{"display":"Kommoss, Stefan","family":"Kommoss","role":"aut","given":"Stefan"},{"given":"Jelena","role":"aut","display":"Boekhoff, Jelena","family":"Boekhoff"},{"display":"Denkert, Carsten","family":"Denkert","role":"aut","given":"Carsten"}],"id":{"eki":["1909392790"],"doi":["10.1016/j.modpat.2024.100445"]},"relHost":[{"id":{"eki":["326643419"],"issn":["1530-0285"],"zdb":["2041318-X"]},"recId":"326643419","physDesc":[{"extent":"Online-Ressource"}],"disp":"Systematic analysis of homologous recombination deficiency testing in ovarian cancer development of recommendations for optimal assay performanceModern pathology","type":{"bibl":"periodical","media":"Online-Ressource"},"note":["Gesehen am 05.01.23","Fortsetzung der Druck-Ausgabe"],"origin":[{"dateIssuedDisp":"1988-","dateIssuedKey":"1988","publisher":"Nature Publishing Group ; Lippincott Williams & Wilkins ; Ovid","publisherPlace":"London ; Hagerstown, Md. ; [Erscheinungsort nicht ermittelbar]"}],"pubHistory":["1.1988 -"],"title":[{"subtitle":"an official journal of the United States and Canadian Academy of Pathology (USCAP)","title_sort":"Modern pathology","title":"Modern pathology"}],"part":{"year":"2024","volume":"37","text":"37(2024), 4, Artikel-ID 100445","issue":"4","extent":"100445-1-100445-10$t10"},"language":["eng"]}],"recId":"1909392790","physDesc":[{"extent":"100445-1-100445-10$t10 S."}],"name":{"displayForm":["Marcel Romey, Fiona Rodepeter, Akira Hattesohl, Kristin Kaiser, Julia Teply-Szymanski, Florian Heitz, Annette Staebler, Violeta Serra, Albert Grass, Frederik Marmé, Kirsten M. Timms, Philipp Harter, Alba Llop-Guevara, Stefan Kommoss, Jelena Boekhoff, Carsten Denkert"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title":"Systematic analysis of homologous recombination deficiency testing in ovarian cancer","subtitle":"development of recommendations for optimal assay performance","title_sort":"Systematic analysis of homologous recombination deficiency testing in ovarian cancer"}],"origin":[{"dateIssuedKey":"2024","dateIssuedDisp":"8 February 2024"}],"note":["Gesehen am 22.11.2024"]} | ||
| SRT | |a ROMEYMARCESYSTEMATIC8202 | ||